Novo Nordisk's (NOVOB DC) CFO says there is still very low penetration in the Chinese obesity drug market as competition has been intense

Novo Nordisk's CFO highlights the low market penetration for obesity drugs in China amidst fierce competition, which suggests potential challenges for future growth in that region.

Newsquawk StaffPublished On the live feed at 6 more headlines followed before this page went public
Newsquawk headlinesUTC

US Labour Department says all agencies will fully resume to normal operations from the 4th of February 2026

Watches of Switzerland (WOSG LN) says Q3 and FY 2026 holiday trading continues strong H1 trends

Novo Nordisk's (NOVOB DC) CFO says there is still very low penetration in the Chinese obesity drug market as competition has been intense

German VDMA Engineering Association December orders comes at -5% Y/Y

EU HCOB Services PMI Final (Jan) 51.6 vs. Exp. 51.9 (Prev. 52.4)

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
  • They are expecting a percentage decline in 2026 US sales in the teens.
Context

The expectation of a significant decline in U.S. sales by 2026 indicates a cautious outlook that could weigh on investor sentiment and affect sector dynamics, especially if peers are also struggling. This situation merits close monitoring for its implications on market positioning and overall revenue forecasts.

Related headlines

The whole workspace, free to try.

Try it free